MedTrace Logo

A Study of ENX-104 in Healthy Participants

NCT07472361 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-22

No results posted yet for this study

Summary

The study is designed to evaluate the relative bioavailability, safety, and tolerability of a single dose of ENX-104 administered orally as a solution fasted, a tablet fasted, or a tablet with a high fat meal in healthy participants

Conditions

  • Healthy Volunteers

Interventions

DRUG

ENX-104

Tablets

DRUG

ENX-104

Oral solution

Sponsors & Collaborators

  • Engrail Therapeutics INC

    lead INDUSTRY

Principal Investigators

  • David George Steel, MBChB · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-25
Primary Completion
2026-03-19
Completion
2026-03-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07472361 on ClinicalTrials.gov